Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.

Hyloris has an eventful year ahead as it plans to conduct numerous trials for products in its ever-expanding pipeline and launch Maxigesic IV in the US.

In something of a surprise, Eagle Pharmaceuticals has announced its exit from the generic vasopressin market – one year after a hard-fought and hard-won launch.

Targeting a dual biologic for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis, Coya Therapeutics has joined forces with abatacept biosimilar developer Dr Reddy’s.

Spain’s Laboratorios Farmacéuticos Rovi has a firm date to remedy issues observed in its application for a hybrid version of risperidone, developed using Rovi’s proprietary ISM drug-release technology platform.

With a number of recent deals under the firm’s belt in both generics and biosimilars, Sandoz CEO Richard Saynor talks to Generics Bulletin about how the firm is integrating new assets and building towards some key launches this year.

Spurred on by “increasing global demand for biosimilar medicines,” Sandoz has revealed plans to invest at least $400m in building a new biologics production plant in Slovenia.

Global health NGO International Health Partners has set out the reasons why manufacturing to donate represents a “strategic and sustainable” way for industry partners to collaborate with the charity on relief efforts.

Akorn is facing questions after suddenly shutting down its operations and terminating its employees, with a chapter 7 bankruptcy filing on the cards. Answers are being sought over why the company did not provide advance warnings to employees given the precarious state of its finances.

The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.

With Amneal delivering what it described as a “solid” set of financials for 2022, the company has reaffirmed that it sees more value in moving increasingly into complex generics and bolstering its nascent biosimilars business.

Revenue falls 33% over the half year for the ailing Australian pharmaceutical as it pivots from generics to the branded market

The AAM has confirmed the departure of three executives, one of whom had also been serving as chair of the IGBA. As a result, the global generics industry association has brought in a new interim chair, at the same time as the head of one of the industry’s largest players has joined its CEO Advisory Committee.

Former Perrigo Rx business Padagis has seen a leadership change, while Celltrion has appointed a new chief commercial officer for the US. Meanwhile, Biosimilars Canada has elected a new chair and Australia’s GBMA has welcomed fresh board members.

The Fresenius group spoke at length about its core Fresenius Kabi business during the company’s year-end financial call, not least its under pressure IV drugs in the US.